Clinical Trials Browser

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) × balstilimab × 90 days × Clear all

NCT06589440 2026-01-15

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Phase 2 Recruiting

Gastrointestinal

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)